drugset / Trial / NCT02654522
The Use of a Recombinant DNA-based Hyaluronidase to Dissolve Fixed Amounts of Hyaluronic Acid Dermal Fillers
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine whether or not Recombinant DNA-based hyaluronidase (RDNAH/Hylenex recombinant), is safe and effective for dissolving hyaluronic acid (HA) dermal fillers.
Timeline
- Start
- 2016-01
- Primary completion
- 2016-02
- Completion
- 2016-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rHuPH20 | Protein / enzyme biologic | 0 iu | Other |
| Subject | rHuPH20 | Protein / enzyme biologic | 30 iu | Other |
| Subject | rHuPH20 | Protein / enzyme biologic | 60 iu | Other |
| Subject | rHuPH20 | Protein / enzyme biologic | 75 iu | Other |
Indications
No indication recorded.